Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated Approval

Mahnum Shahzad; Huseyin Naci; Anita K Wagner

doi:10.1001/jamainternmed.2021.5989

Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated Approval

JAMA Intern Med. 2021 Dec 1;181(12):1673-1675. doi: 10.1001/jamainternmed.2021.5989.

Authors

Mahnum Shahzad¹, Huseyin Naci², Anita K Wagner¹

Affiliations

¹ Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
² Department of Health Policy, London School of Economics and Political Science, London, United Kingdom.

Abstract

This exploratory study assesses estimated Medicare spending on 10 cancer drug indications that lacked overall survival benefit after receiving US Food and Drug Administration accelerated approval.

MeSH terms

Drug Approval / economics
Drug Approval / legislation & jurisprudence*
Follow-Up Studies
Humans
Medicare / economics*
Neoplasms / drug therapy*
Neoplasms / economics
Retrospective Studies
United States
United States Food and Drug Administration*